Polyclonal Antibody to DR5/Apo2/TRAIL-R2/TRAILR2/TRICK2/KILLER Please contact your local IMGENEX distributor for pricing on these products.
author: Devi Sankar Prasad Dash (ddash AT imgenex dot com)
Polyclonal Antibody to DR5/Apo2/TRAIL-R2/TRAILR2/TRICK2/KILLER Please contact your local IMGENEX distributor for pricing on these products.Trastuzumab (Herceptin) Enhances...
author: Devi Sankar Prasad Dash (ddash AT imgenex dot com)
FISH, HER-2/neu, Paraffin Block FISH, HER-2/neu, Paraffin Block Test Summary Clinical Use Assess eligibility for trastuzumab (Herceptin ®´ ) treatment in breast cancer patients Assess prognosis of stage II, node-positive breast cancer patients Predict disease-free and overall survival in patients with stage II, node-positive breast cancer treated with adjuvant cyclophosphamide, doxorubicin, 5...
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
Cancer: Breast Disorders: Merck Manual Home Edition Section Women's Health Issues Subject Breast Disorders Cancer Breast cancer is the second most common cancer among women after skin cancer and, of cancers, is the second most common cause of death among women after lung cancer.
Immunotherapy: Prevention and Treatment of Cancer: Merck Manual Home Edition Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
Cancer: Breast Disorders: Merck Manual Home Edition Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
THE MERCK MANUAL OF GERIATRICS, App. III, Trade Names of Some Commonly Used Drugs, GANTANOL to LYSODREN Trade Names of Some Commonly Used Drugs TRADE AND GENERIC NAMES OF COMMONLY USED DRUGS GANTANOL to LYSODREN Trade Name Generic GANTANOL Sulfamethoxazole GANTRISIN Sulfisoxazole GARAMYCIN Gentamicin GEOCILLIN Carbenicillin GLUCOPHAGE Metformin GLUCOTROL Glipizide GRIFULVIN V Griseofulvin GRISACTIN Griseofulvin HALCION Triazolam HALDOL Haloperidol HALDRONE Paramethasone HALOTESTIN...
THE MERCK MANUAL OF GERIATRICS, App. III, Trade Names of Some Commonly Used Drugs. Salmeterol to Zolpidem Trade Names of Some Commonly Used Drugs GENERIC AND TRADE NAMES OF COMMONLY USED DRUGS Salmeterol to Zolpidem Generic Trade Name Salmeterol SEREVENT Salsalate DISALCID, SALFLEX Saquinavir FORTOVASE Sargramostim LEUKINE Secobarbital SECONAL Selegiline ELDEPRYL Selenium SELSUN Sertraline ZOLOFT Sibutramine MERIDIA Sildenafil VIAGRA Silver sulfadiazine SILVADENE Simethicone MYLICON...
GPC-Biotech Home Deutsch About the Company Anticancer Programs Technologies Investor Relations News &-Media Careers Calendar Contact/- Imprint Sitemap Search Glossary Forward Look-ing Statements Overview Strategy Executive Committee Supervisory Board Locations Overview Satraplatin Monoclonal Antibody Cdk Inhibitors Research Programs Growing the Pipeline Alliances Stock Key Figures Financial...
author: Form+Fakten, Maximilian Vollendorf
Genentech: Investor Relations - Financials - 2001 First Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2001 First Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2001 Third Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2002 First Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2003 Third Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2003 Third Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2004 Second Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year Financial Summary Literature...
Genentech: Investor Relations - Financials - 2004 First Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2004 First Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 1998 Third Quarter Report Food and Drug Administration sent Genentech this letter indicating its approval for Genentech to market Herceptin ® (Trastuzumab) for the treatment of metastatic breast cancer in patients whose tumors overexpress HER2.
Genentech: Investor Relations - Financials - 2000 Second Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2000 Second Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2001 Second Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2001 Second Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2001 Third Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2001 Third Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2003 Second Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2003 Second Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2002 Second Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2002 Second Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2002 Third Quarter Report We are also moving forward with our development programs for our existing products, Rituxan and Herceptin ® (Trastuzumab), deepening our knowledge of these molecules and developing further indications within the same disease category or indications for entirely other disease groups.Herceptin, the adjuvant breast cancer program continues to...
Genentech: Research - Researcher Profiles - Mark Sliwkowski Home Contact Us Site Index Search [ Research -- Researcher Profiles -- Mark Sliwkowski ] Researcher Profiles Home Research Antibody Engineering Assay & Automation Technology Bioinformatics Immunology Medicinal Chemistry Molecular Biology Molecular Oncology Vishva Dixit Avi Ashkenazi Napoleone Ferrara Ellen Filvaroff Hans-Peter Gerber Diane Pennica Paul Polakis Mark Sliwkowski---...
Genentech: Investor Relations - Financials - 2003 First Quarter Report Total product sales increased to $598.5 million compared to $476.5 million in the first quarter of 2002, driven primarily by growth in the combined sales of Rituxan® (Rituximab) and Herceptin ® (Trastuzumab), which made up 73% of Genentech's first quarter 2003 total net product sales.Herceptin for ex-U.S.
